계명대학교 의학도서관 Repository

Long-Term Survival Outcomes of Elderly Patients Treated With S-1 or Capecitabine Plus Oxaliplatin for Stage II or III Gastric Cancer: A Multicenter Cohort Study

Metadata Downloads
Author(s)
Seohee ChoiJae-Seok MinSang-Ho JeongMoon-Won YooYoung-Gil SonSung Jin OhJong-Han KimJoong-Min ParkHoon HurYe Seob JeeSun-Hwi HwangSung-Ho JinSang Eok LeeYoung-Joon LeeKyung Won SeoSungsoo ParkChang Min LeeChang Hyun KimIn Ho JeongHan Hong LeeSung Il ChoiSang-Il LeeChan-Young KimHyundong ChaeMyoung-Won SonKyung Ho PakSungsoo KimMoon-Soo LeeHyoung-Il Kim
Keimyung Author(s)
Son, Young Gil
Department
Dept. of Surgery (외과학)
Journal Title
J Gastric Cancer
Issued Date
2022
Volume
22
Issue
1
Keyword
Adjuvant chemotherapyGastric cancerElderlySurvivalRecurrence
Abstract
Purpose:
Tegafur/gimeracil/oteracil (S-1) and capecitabine plus oxaliplatin (CAPOX) are standard adjuvant chemotherapies (ACs) administered after gastrectomy to patients with stage II or III gastric cancer. However, the efficacy of AC in elderly patients remains unclear. The objective of this retrospective multicenter cohort study was to compare the efficacies of S-1 and CAPOX AC in patients aged ≥70 years.

Materials and Methods:
Nine hundred eighty-three patients who were treated with AC using S-1 (768 patients) or CAPOX (215 patients) were enrolled in this study. Each patient underwent AC after curative gastrectomy for stage II or III gastric cancer at one of 27 hospitals in the Republic of Korea between January 2012 and December 2013. Relapse-free survival (RFS) and overall survival (OS) were analyzed according to AC regimen and age group.

Results:
Of the 983 patients, 254 (25.8%) were elderly. This group had a similar RFS (P=0.099) but significantly poorer OS (p=0.003) compared with the non-elderly group. Subgroup analysis of the non-elderly group revealed no AC-associated differences in survival. Subgroup analysis of the elderly group revealed significantly better survival in the S-1 group than in the CAPOX group (RFS, P<0.001; OS, P<0.001). Multivariate analysis revealed that the CAPOX regimen was an independent poor prognostic factor for RFS (hazard ratio [HR], 1.891; 95% confidence interval [CI], 1.072–3.333; P=0.028) and OS (HR, 2.970; 95% CI, 1.550–5.692; P=0.001).

Conclusions:
This multicenter observational cohort study found significant differences in RFS and OS between S-1 and CAPOX AC among patients with gastric cancer aged ≥70 years.
Keimyung Author(s)(Kor)
손영길
Publisher
School of Medicine (의과대학)
Citation
Seohee Choi et al. (2022). Long-Term Survival Outcomes of Elderly Patients Treated With S-1 or Capecitabine Plus Oxaliplatin for Stage II or III Gastric Cancer: A Multicenter Cohort Study. J Gastric Cancer, 22(1), 67–77. doi: 10.5230/jgc.2022.22.e6
Type
Article
ISSN
2093-5641
Source
https://www.jgc-online.org/DOIx.php?id=10.5230/jgc.2022.22.e6
DOI
10.5230/jgc.2022.22.e6
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/44078
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Surgery (외과학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.